Nuvation Bio, Inc.
(NYSE : NUVB)

( )
NUVB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 6.42%282.350.0%$4047.51m
BNTXBioNTech SE 8.17%302.690.0%$1321.33m
NVAXNovavax, Inc. 28.90%182.8578.2%$874.24m
AMGNAmgen, Inc. 1.21%211.321.4%$643.80m
GILDGilead Sciences, Inc. 0.22%69.651.0%$510.30m
LGVNLongeveron Inc. -3.31%19.580.0%$453.36m
VRTXVertex Pharmaceuticals, Inc. 0.08%205.221.9%$451.66m
REGNRegeneron Pharmaceuticals, Inc. 1.61%635.092.7%$406.05m
ILMNIllumina, Inc. 5.06%369.433.3%$341.03m
SNSSSunesis Pharmaceuticals, Inc. 2.38%4.310.7%$301.28m
BIIBBiogen, Inc. 1.21%226.831.8%$284.75m
SGENSeagen Inc. 0.30%146.445.8%$152.49m
INCYIncyte Corp. 2.65%66.732.4%$150.12m
EXASEXACT Sciences Corp. 3.12%83.3618.0%$145.51m
BMRNBioMarin Pharmaceutical, Inc. 2.23%86.124.2%$137.03m

Company Profile

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.